Nicotine Bitartrate Dihydrate:Exports & Compliance White Paper 2026

I. Executive Summary

Nicotine bitartrate dihydrate (CAS 6019-06-3) is the tartaric acid salt of nicotine, a pyridine-pyrrolidine alkaloid that is among the most strictly regulated molecules in legitimate chemical trade. This white paper is written deliberately to the strictest compliance standard. Nicotine is acutely toxic by oral, dermal and inhalation routes, it is the defining constituent of tobacco products, and it is separately regulated when used as a pesticide active substance and when incorporated into licensed medicinal products. The material described here is supplied only to licensed, verified industrial and laboratory customers under end-use declaration and know-your-customer screening. Nothing in this paper is consumer guidance, inhalation-safety assurance, device or e-liquid formulation advice, or dosing information.

Technically the compound is a salt of (S)-3-(1-methylpyrrolidin-2-yl)pyridine with tartaric acid, isolated as a dihydrate. Salt formation converts a volatile, dermally absorbable free base into a crystalline, water-soluble, weighable solid, which is the principal reason the salt is traded. Commercial quality therefore turns on three variables: acid-to-base stoichiometry, water of crystallisation, and the minor alkaloid profile. Those variables also carry regulatory weight, because the alkaloid fingerprint is the evidence regulators and customers use to distinguish tobacco-extracted from synthetic nicotine.

The compliance perimeter is the dominant commercial fact. In the European Union, nicotine-containing electronic cigarettes and refill containers fall under Directive 2014/40/EU, with ingredient and emission notification, concentration limits and packaging rules, while REACH and CLP impose acute-toxicity classification and exposure documentation. In the United States, FDA's deeming rule brings all tobacco products within premarket review, and the PACT Act governs registration and carriage. China operates a tobacco monopoly with dedicated e-cigarette rules. Buyer qualification, end-use declaration and diversion control are not optional overhead; they are the licence to operate.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

Nicotine is a diprotic base: the pyrrolidine nitrogen has a pKa of roughly 8 and the pyridine nitrogen a pKa near 3. Salt formation with a hydroxy-dicarboxylic acid such as L-(+)-tartaric acid yields a crystalline, water-soluble solid that is far safer to weigh, transfer and formulate in an industrial setting than the volatile free base, which readily penetrates skin. The dihydrate form is hygroscopic and light-sensitive, oxidising over time to nicotine-N-oxide and cotinine, so solid-form control and storage conditions are specification items rather than packaging niceties.

• Salt stoichiometry, water of crystallisation and solid form: Commercial lots are traded against a nicotine base equivalence determined by titration or HPLC, because acid-to-base ratio and hydration state both shift the mass fraction. Thermogravimetric analysis and Karl Fischer titration fix the two waters, XRPD and DSC confirm form, and control of deliquescence drives packaging. Buyers should treat any quotation without a declared stoichiometry and hydration as incomplete.
• Minor alkaloid profile as provenance and quality evidence: Nornicotine, anatabine, anabasine, myosmine, cotinine and nicotine-N-oxide are routinely profiled by GC-MS or LC-MS/MS. Tobacco-extracted material also carries tobacco-specific nitrosamines and polycyclic aromatic hydrocarbon residues absent from synthetic material, which makes the fingerprint a provenance marker in disputes and in regulatory filings. Enantiomeric purity, with R-nicotine as the marker impurity, should be reported by chiral method.

2.2 Synthesis and Manufacturing Technologies

Two provenances exist and the choice between them has legal consequences, not merely analytical ones. Industrial practice is described here at the level of route class, purification strategy and containment only; no detail that could facilitate unlicensed production or diversion is provided. In both cases, salt formation and crystallisation are executed in closed systems with operator exposure control.

• Tobacco extraction versus synthetic nicotine: Extractive supply begins with Nicotiana biomass, alkaline liberation, liquid-liquid extraction and high-vacuum fractionation, then conversion to the salt; it brings minor tobacco alkaloids and nitrosamine residues. Synthetic supply builds the pyrrolidine ring from pyridine-building blocks with a stereocontrolled or resolution step, giving a narrower impurity profile. Regulators increasingly require the provenance to be declared, and several jurisdictions have closed the distinction by defining tobacco products by nicotine content rather than by botanical source.
• Salt formation, crystallisation and containment engineering: The free base is charged to a closed reactor under nitrogen and combined with tartaric acid in alcoholic or aqueous-alcoholic solvent at controlled stoichiometry, followed by low-temperature crystallisation, centrifugation and drying below the dehydration threshold. Because occupational exposure limits for nicotine are low, campaigns are typically run with a health-based exposure limit and an assigned containment band, closed charging, dedicated or well-documented cleaning validation, and wipe testing.

2.3 Core Application Matrix

• Analytical and reference standard use, RUO: Calibration standards and reference materials for tobacco and nicotine analysis, metabolism studies and residue laboratories, sold in small packs to verified institutions. Sales are conditioned on end-use declaration and customer qualification, and material is not supplied for human or veterinary administration.
• Ingredient supply to licensed tobacco-product manufacturers: Supply into regulated manufacturing chains where the finished product itself must hold its own authorisation, notification or marketing authorisation. The raw material supplier supports the customer's filing with impurity, stability and emissions-relevant data, but never substitutes for the product-level approval.
• Separate pesticide and medicinal registration tracks: Nicotine used as a crop-protection active substance requires its own registration, and it is not an approved active substance under Regulation (EC) 1107/2009 in the European Union. Medicinal use is a GMP and marketing-authorisation pathway entirely distinct from RUO supply. Neither track is opened by purchasing the salt.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Underlying demand is driven by the global nicotine-products industry, yet the trend that matters to chemical suppliers is regulatory hardening rather than volume growth. Concentration caps, notification duties, flavour restrictions and excise regimes in major markets have pushed legitimate buyers toward suppliers able to support a filing, and pushed illegitimate demand toward diversion. The practical result is a market where documentation capability, audit readiness and chain-of-custody integrity determine who can sell at all, and where a supplier's customer list is itself a compliance asset.

3.2 Capacity Distribution and Export Flows

Tobacco-derived nicotine capacity follows leaf sourcing, concentrated in China, India and leaf-exporting origins, whereas synthetic capacity sits with fine-chemical producers in China, the United States and Europe that can run stereocontrolled routes at scale. Conversion to the bitartrate salt is a relatively small finishing step, so salt capacity is rarely the constraint; access to compliant nicotine base and to the licences needed to hold and move it is. Export flows are correspondingly tight, with licensed, documented channels dominating and spot trading increasingly excluded by carrier and payment-provider policy.

3.3 Market Bifurcation and Pricing Dynamics

Prices reflect risk allocation as much as chemistry. Salt form commands a premium over free base because of handling and packaging discipline, and lots with declared stoichiometry, verified hydration, a full minor-alkaloid profile, nitrosamine data where relevant, heavy-metal data to ICH Q3D or USP limits, and stability support command a further premium. Discount material offered without end-use screening or provenance documentation should be read as a diversion risk rather than a bargain, and the cost of lost licences dwarfs any unit-price saving.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Nicotine is regulated simultaneously as a toxic chemical, as the defining constituent of tobacco products, as a pesticide active substance and, in licensed form, as a medicine. A supplier must satisfy all applicable layers for the specific destination and declared end use, and must verify that the customer holds the licence its own activity requires. The following instruments are the minimum map.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• Directive 2014/40/EU (Tobacco Products Directive) and national nicotine rules: Article 20 governs electronic cigarettes and refill containers: prior notification to the member-state authority, ingredient and emission reporting, a maximum nicotine concentration of 20 mg per millilitre, refill containers limited to 10 millilitres and tanks to 2 millilitres, child-resistant and tamper-evident packaging, health warnings and registration for cross-border distance sales. Nicotine pouches and other nicotine products outside the directive are governed by divergent national law, which must be checked market by market.
• REACH, CLP and the plant-protection exclusion: Nicotine carries harmonised acute-toxicity classification across oral, dermal and inhalation routes, with aquatic hazard classification, which drives SDS content, exposure scenarios, packaging group and transport declaration. Registration status and any authorisation or restriction listing must be verified before supply. Separately, nicotine is not an approved active substance under Regulation (EC) 1107/2009, so no EU plant-protection use may be supplied.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• FDA tobacco authorities: deeming rule, PMTA and TPMF: The 2016 deeming rule extended FDA authority to all products made or derived from tobacco, and the 2022 amendment to the tobacco-product definition closed the synthetic-nicotine gap, so premarket authorisation is now required across sources. New products generally need a premarket tobacco application or a substantial-equivalence route, registration and product listing, ingredient listing and harmful-constituent reporting, with supporting data often supplied through a tobacco product master file rather than by the raw-material vendor.
• PACT Act, taxation and carriage: The Prevent All Cigarette Trafficking Act as amended requires seller registration with federal and state authorities, monthly filings, and largely forecloses carriage of covered products by the postal service, while federal, state and local excise regimes apply to finished goods. Carriers and payment providers impose their own policies, so logistics design must be validated before dispatch. Pesticide uses remain under EPA and FIFRA, and child-resistant packaging is required under the Poison Prevention Packaging Act.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Environmental and governance performance is inseparable from market access in this category. Extraction routes consume solvent and water and generate alkaloid-bearing effluent; tobacco leaf sourcing carries labour and agrochemical scrutiny; and the governance dimension, prevention of diversion to unlicensed or youth-accessible channels, is the material ESG risk that investors and customers now audit.

5.1 Carbon Footprint and Circular Economy

Footprint reduction starts with solvent recovery in extraction and purification, heat integration on concentrators and dryers, and responsible destruction of alkaloid-bearing waste streams, which are typically hazardous and must be treated rather than discharged. Cold-chain and secure-freight requirements raise distribution emissions, so lane consolidation and validated thermal packaging matter. Producers with ISO 14001 and credible Scope 1 and 2 reporting increasingly win listings purely on audit readiness.

5.2 Sustainable Sourcing and Traceability

Traceability means more than a batch number. Buyers should require leaf origin, grower or contract-farming programme, agrochemical and residue records for tobacco-derived material, and for synthetic material the route class and solvent inventory. Custody must be continuous and reconciled: secure warehousing, access control, serialized containers, discrepancy investigation and documented destruction of rejects and returns, with the same discipline applied to laboratory-scale lots.

VI. Supply Chain Resilience and Export Logistics

Nicotine and its preparations are consigned under UN 1654 as toxic substances of Class 6.1, with packing group and subsidiary provisions determined by form and concentration, moving under ADR, IMDG and IATA rules in UN-specification packaging. Because the substance is toxic by skin contact as well as ingestion, packaging integrity, labelling and documentation are treated as safety controls.

6.1 Packaging Standards and Moisture/Contamination Control

• UN-specification primary packaging with moisture and light barrier: Sealed amber glass or compatible lined containers with tamper-evident and child-resistant closures, moisture barrier and inert headspace, filled to limit oxidation and deliquescence. Serial numbers on every container support reconciliation and investigation, and compatibility of closure materials with the acidic salt should be demonstrated rather than assumed.
• Temperature and humidity control with validated lanes: Cool, dry storage is standard, with many shippers specifying controlled temperature and desiccant-protected sealed secondary packaging, data loggers on sensitive lanes and defined excursion handling. Receiving sites should inspect seals before opening, record container numbers, and quarantine material whose integrity is in doubt.

6.2 Dangerous Goods Identification and Transit Protocols

Consignments require a competent dangerous-goods declaration, UN-specification packaging, trained shippers and carriers, and routes that avoid prohibited carriage channels; postal and parcel pathways are frequently unavailable or unlawful for covered products. Declarations normally fall within HS chapter 2939 for alkaloids and their salts, verified against destination tariff practice, and licences or permits must be evidenced before collection. Chain-of-custody documentation, signature capture and inventory reconciliation should be maintained end to end, with deviations investigated and recorded.

VII. Enterprise Global Expansion Strategy Guide

Growth in this category is available only to suppliers who treat compliance as the product. Three priorities define a defensible position.

1. Qualify the customer before qualifying the molecule: Implement a documented know-your-customer programme: corporate identity and licence verification, end-use declaration, restricted-party screening, assessment of the buyer's downstream distribution and age-restriction controls, and periodic re-qualification. Decline business that cannot be evidenced, and record the decision.
2. Build dossier-grade documentation: Offer a certificate of analysis with stoichiometry, hydration, assay, minor alkaloid profile, enantiomeric purity, heavy metals and residual solvents, plus a stability protocol, an SDS consistent with the harmonised acute-toxicity classification, and support packages that let customers reference the material in tobacco product master files and notifications without the supplier making product-level claims.
3. Map market entry jurisdiction by jurisdiction: Treat each destination as a separate project: EU notification and concentration limits, US premarket and PACT Act obligations, China's tobacco monopoly and e-cigarette measures, and separate pesticide registration where that use is intended. Maintain a regulatory watch, since this is the fastest-moving regime in speciality chemicals.

VIII. Conclusion

Nicotine bitartrate dihydrate is a case study in how regulation, not chemistry, sets the terms of trade. The molecule is well understood, the salt is straightforward to manufacture, and finishing capacity is plentiful. What is scarce is the ability to evidence entitlement: to show that the customer is licensed, that the declared end use is lawful in the destination, that the consignment moved through permitted channels, and that no unit leaked to an unlicensed or youth-accessible market.

Suppliers that invest in customer qualification, dossier-grade analytics and chain-of-custody integrity will find durable demand among licensed manufacturers and verified laboratories, and will be resilient when a jurisdiction tightens again. Suppliers that compete on price and paperwork shortcuts are not merely taking commercial risk; they are the mechanism through which diversion occurs, and they are the intended target of enforcement.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Nicotine bitartrate dihydrate Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Nicotine bitartrate dihydrate supply chain:

• China, leaf-derived nicotine and licensed synthetic capacity: Production is anchored in Yunnan and neighbouring tobacco-growing provinces, with synthetic capacity in coastal fine-chemical clusters. Activity is governed by the tobacco monopoly and e-cigarette measures, so exportable supply depends on licences and the national trading platform rather than on open-market availability.
• United States, synthetic nicotine and FDA-facing documentation: Producers of synthetic nicotine combine stereocontrolled synthesis with FDA-facing capability, supporting customers through premarket review, registration and listing, and tobacco product master files, alongside analytical-standard houses serving residue and metabolism laboratories.
• European Union, REACH-compliant finishing and NRT-grade supply: EU and UK operators specialise in REACH and CLP-compliant salt finishing, controlled-substance-grade warehousing and GMP supply for licensed medicinal nicotine replacement products, offering the documentation depth that member-state authorities expect on inspection.